CDKN2A and central nervous system cancer: Gain of EGFR and loss of PTEN and CDKN2A occur together frequently in both IDHwt lower grade and grade IV gliomas (all three occurring together in 53 % and 40 %, respectively), with no significant differences of these alterations by grade.